FDA takes 3, or within 4 weeks? to provide feedback.
meeting was 19th April. This monday will be 2 full weeks since the meeting, starting the third week. I would think it's quite possible that feedback will arrive this coming week, if it hasnt already.
Given this feedback is critical and price sensitive, isnt ANP legally obliged to inform us of it? I understand they want to have it "in hand" as evidence to negotiate partnerships with, and its nice they've told us this... "that we wont hear until end may" but is that fair? Isnt any price sensitive news needing to be provided to us the part owners as soon as possible?
Sitting on the FDAs feedback for 2-3 weeks to "gather their thoughts" / cut a deal with doesnt feel transparent or fair to us the shareholders.
so far the communication is good. But the day that info from FDA arrives I want to know about it, and I dont think sharing the news would inhibit any deals.
if they are using it to shop for partnerships or negotiate, this then becomes public knowledge, regardless of them saying keep it confidential in any negotiations... the feedback is out there, when it should first be delivered as an announcement so we're all on the same footing. You never know... someone left field might have a spare 30million dollars and want to invest, but wont know about the fda feedback until its too late if announced end may together with a partner.
i would like a news flow eg "fda feedback received. Blah blah... we look forward to informing further updates re companys plans moving forward".
- Forums
- ASX - By Stock
- Ann: US FDA Type C Meeting for ATL1102 in DMD
PER
percheron therapeutics limited
Add to My Watchlist
5.26%
!
1.0¢

FDA takes 3, or within 4 weeks? to provide feedback.meeting was...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.001(5.26%) |
Mkt cap ! $10.33M |
Open | High | Low | Value | Volume |
1.0¢ | 1.0¢ | 1.0¢ | $198 | 19.81K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 986347 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 1723383 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 986347 | 0.009 |
6 | 3248000 | 0.008 |
2 | 1142857 | 0.007 |
1 | 1000000 | 0.006 |
3 | 4199997 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 1723383 | 6 |
0.011 | 2342858 | 8 |
0.012 | 2658324 | 5 |
0.013 | 691461 | 3 |
0.014 | 1572000 | 3 |
Last trade - 10.00am 02/07/2025 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Dr. Steven Gourlay, CEO
Dr. Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online